| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population
|
Heredia, David
|
|
|
174 |
C |
p. 133-140
|
artikel
|
| 2 |
Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study
|
Chan, Jeffrey Shi Kai
|
|
|
174 |
C |
p. 67-70
|
artikel
|
| 3 |
Chemoradiation-induced pneumonitis in patients with unresectable stage III non-small cell lung cancer: A systematic literature review and meta-analysis
|
Kuang, Yuting
|
|
|
174 |
C |
p. 174-185
|
artikel
|
| 4 |
Comparison of discrimination performance of 11 lung cancer risk models for predicting lung cancer in a prospective cohort of screening-age adults from Germany followed over 17 years
|
Bhardwaj, Megha
|
|
|
174 |
C |
p. 83-90
|
artikel
|
| 5 |
Contents
|
|
|
|
174 |
C |
p. v-vi
|
artikel
|
| 6 |
Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC
|
Chen, Ping
|
|
|
174 |
C |
p. 157-164
|
artikel
|
| 7 |
Editorial Board
|
|
|
|
174 |
C |
p. iii
|
artikel
|
| 8 |
EGFR testing in paraffin-embedded cell block cytology material is reliable with increased detection for effusion fluid
|
Ng, Joanna Ka Man
|
|
|
174 |
C |
p. 97-103
|
artikel
|
| 9 |
Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial
|
Liu, Yufei
|
|
|
174 |
C |
p. 112-117
|
artikel
|
| 10 |
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC
|
Salomone, Fabio
|
|
|
174 |
C |
p. 36-44
|
artikel
|
| 11 |
IL-9 stimulates an anti-tumor immune response and facilitates immune checkpoint blockade in the CMT167 mouse model
|
Feng, Yuqian
|
|
|
174 |
C |
p. 14-26
|
artikel
|
| 12 |
Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy
|
Justeau, Grégoire
|
|
|
174 |
C |
p. 45-49
|
artikel
|
| 13 |
Leptomeningeal metastases in non-small cell lung cancer: Diagnosis and treatment
|
Wang, Yan
|
|
|
174 |
C |
p. 1-13
|
artikel
|
| 14 |
Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report
|
Trabelsi Grati, Olfa
|
|
|
174 |
C |
p. 186-187
|
artikel
|
| 15 |
Lung cancer in never smokers: Distinct population-based patterns by age, sex, and race/ethnicity
|
Pinheiro, Paulo S.
|
|
|
174 |
C |
p. 50-56
|
artikel
|
| 16 |
Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non–small cell lung cancer: A multiplex immunohistochemistry–based single-cell analysis
|
Isomoto, Kohsuke
|
|
|
174 |
C |
p. 71-82
|
artikel
|
| 17 |
MET inhibitors for MET amplification—What’s the most appropriate detection method and cut-off value?
|
Zhang, Liwei
|
|
|
174 |
C |
p. 172-173
|
artikel
|
| 18 |
NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy
|
Trummer, Arne
|
|
|
174 |
C |
p. 141-145
|
artikel
|
| 19 |
Pathologic node-negative lung cancer: Adequacy of lymph node yield and a tool to assess the risk of occult nodal disease
|
Tan, Kay See
|
|
|
174 |
C |
p. 60-66
|
artikel
|
| 20 |
Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer
|
Mazieres, Julien
|
|
|
174 |
C |
p. 146-156
|
artikel
|
| 21 |
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience
|
De Giglio, Andrea
|
|
|
174 |
C |
p. 91-96
|
artikel
|
| 22 |
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP)
|
Passaro, Antonio
|
|
|
174 |
C |
p. 118-124
|
artikel
|
| 23 |
Prognostic impact of tumour mutational burden in resected stage I and II lung adenocarcinomas from a European Thoracic Oncology Platform Lungscape cohort
|
Bubendorf, Lukas
|
|
|
174 |
C |
p. 27-35
|
artikel
|
| 24 |
Spread through air spaces is a powerful prognostic predictor in patients with completely resected pathological stage I lung adenocarcinoma
|
Shimomura, Masanori
|
|
|
174 |
C |
p. 165-171
|
artikel
|
| 25 |
The first historical description of malignant mesotheliomas
|
Drouin, Emmanuel
|
|
|
174 |
C |
p. 57-59
|
artikel
|
| 26 |
The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma
|
Tamiya, Yutaro
|
|
|
174 |
C |
p. 125-132
|
artikel
|
| 27 |
Type of lymphadenectomy does not influence survival in pIa NSCLC patients who underwent VATS lobectomy: Results from the national VATS group database
|
Chiappetta, Marco
|
|
|
174 |
C |
p. 104-111
|
artikel
|
Tijdschrift beschrijving